The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operator agreement with CircleHealth for Harley St

12 Oct 2015 07:00

RNS Number : 8892B
Advanced Oncotherapy PLC
12 October 2015
 

12 October 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Operator agreement with CircleHealth for Harley St site

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed a joint venture agreement with CircleHealth ("Circle") to operate the Company's proton beam cancer therapy centre in Harley Street.

 

Circle, owned by AIM-listed Circle Holdings plc (AIM: CIRC) which is an employee co-owned company, runs hospitals and healthcare across the UK. It has nearly 2,000 partners, working across four UK sites.

 

Under the terms of the agreement, Advanced Oncotherapy and Circle will jointly own a newly formed company into which funding of £6 million will be provided in equal portions by the parties and will cover, inter alia, pre-opening costs and working capital. The arrangement, together with further definitive agreements to be finalised in the coming months, would combine Circle's clinician-led operating model with Advanced Oncotherapy's next-generation proton therapy systems for cancer treatment. Once the centre commences operation the equity in the operating company will be owned as to 50.1% by Circle and the remaining 49.9% by Advanced Oncotherapy.

 

The Harley Street facility will house the UK's first high energy proton beam cancer therapy centre. Circle Health will take responsibility for all operational and clinical matters at the facility as well as the additional procurement, fit-out and facility testing requirements needed for full commissioning and beyond the testing required during the technical development of the system. Circle Health will also take responsibility for insurance provision for the centre. Advanced Oncotherapy will take responsibility for all technical matters. A number of proposals from international financial institutions concerning the provision of vendor finance for the LIGHT technology in Harley Street are being considered.

 

The LIGHT (short for Linac Image Guided Hadron Technology) system, is a proprietary proton accelerator that will offer healthcare providers affordable proton therapy systems to treat cancer using a technology that in many instances can produce better health outcomes and lower treatment related side effects. The LIGHT system achieves the required energy levels found in legacy proton therapy machines but in a unit that is a fraction of the size and significantly lower in cost. The compact configuration of the LIGHT system lends itself perfectly to the installation of this technology in such central city locations, and the Harley Street site will house London's first ever proton therapy unit.

 

The Company is also in discussions with Circle surrounding an agreement to supply its LIGHT system alongside CircleHealth's planned new-build independent hospital in Edgbaston, Birmingham.

 

Steve Melton, Chief Executive of CircleHealth, said:

 

"This is great news for patients, for Circle and for Advanced Oncotherapy. Advanced Oncotherapy is creating a genuinely revolutionary technology, at the cutting edge of cancer treatment. We're delighted to be working with them. When completed this deal means the expansion of Circle into London - giving us a presence in one of the world's greatest medical centres - and into cancer care, where there is huge potential for new technologies and exciting new treatments. For Circle, this is a clear signal of our intention to grow and expand, by combining our experience in operations with other organisations' specialist skills."

 

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said:

 

"Circle Health has a great record for providing innovative healthcare delivery and are the ideal candidate to operate our flagship Harley Street site. Whilst we expect our ongoing business model to focus on Advanced Oncotherapy as a manufacturer of cutting edge proton therapy systems, we felt it was crucial, given the strategic importance of our first site in Harley Street, to have a vested interest in the ongoing operational success of our facility. Working alongside Circle Health, we expect it to transform the UK's approach to cancer radiotherapy treatment."

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 (0)20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 (0)20 7601 6100

Beaufort Securities (Joint Broker)

Jon Levinson / Zoe Alexander

Tel: +44 (0)20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 (0)20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
JVEMBBTTMBTBTAA
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.